These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 28502030)
1. Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis. Tashkandi H; Moore EM; Tomlinson B; Goebel T; Sadri N Ann Hematol; 2017 Aug; 96(8):1417-1418. PubMed ID: 28502030 [No Abstract] [Full Text] [Related]
2. Somatic mutations of calreticulin in myeloproliferative neoplasms. Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356 [TBL] [Abstract][Full Text] [Related]
3. High resolution melting analysis: a rapid and accurate method to detect CALR mutations. Bilbao-Sieyro C; Santana G; Moreno M; Torres L; Santana-Lopez G; Rodriguez-Medina C; Perera M; Bellosillo B; de la Iglesia S; Molero T; Gomez-Casares MT PLoS One; 2014; 9(7):e103511. PubMed ID: 25068507 [TBL] [Abstract][Full Text] [Related]
4. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134 [No Abstract] [Full Text] [Related]
5. Essential thrombocythaemia with mutation in Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356 [TBL] [Abstract][Full Text] [Related]
6. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients. Zaidi U; Sufaida G; Rashid M; Kaleem B; Maqsood S; Mukry SN; Khan RZA; Munzir S; Borhany M; Shamsi TS BMC Cancer; 2020 Mar; 20(1):205. PubMed ID: 32164591 [TBL] [Abstract][Full Text] [Related]
7. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome. Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689 [No Abstract] [Full Text] [Related]
8. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766 [TBL] [Abstract][Full Text] [Related]
9. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950 [TBL] [Abstract][Full Text] [Related]
11. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Rumi E; Cazzola M Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026 [TBL] [Abstract][Full Text] [Related]
12. Calreticulin mutation profile in Indian patients with primary myelofibrosis. Sazawal S; Singh N; Mahapatra M; Saxena R Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795 [TBL] [Abstract][Full Text] [Related]
13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
14. JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia. Pich A; Riera L; Francia di Celle P; Beggiato E; Benevolo G; Godio L Acta Haematol; 2018; 140(4):234-239. PubMed ID: 30404086 [TBL] [Abstract][Full Text] [Related]